This analysis discusses findings from the 2025 KFF Employer Health Benefits Survey, with insights gained from interviews and group discussions with human resources directors and others who manage employer health benefits
About this article Cite this article Zhang, H., Yang, Y., Zhang, M
(Berl) 232 (23), 43034316
If these results are reproduced in humans, people using GLP-1 receptor agonists might be drinking an amount of alcohol that does not normally put them above the legal blood alcohol level, but because they are taking this drug, it does, says Mehal
An increase of 0.2 to 0.3 mg/dL (18 to 27 mol/L) is consistent with creatine's known substrate effect and does not require action beyond documentation
So ,how do you see the recommendations for using ketogenic therapy to treat, serious mental illness or the clinical use of GLP-1s